Sugammadex, a neuromuscular blockade reversal agent, causes neuronal apoptosis in primary cultures

International Journal of Medical Sciences

Volumn 10, Issue 10, 2013, Pages 1278-1285

  Palanca, José M ^a   Aguirre Rueda, Diana ^a   Granell, Manuel V ^a   Aldasoro, Martin ^a   Garcia, Alma ^a   Iradi, Antonio ^a   Obrador, Elena ^a   Mauricio, Maria Dolores ^a   Vila, Jose ^a   Gil Bisquert, Anna ^a   Valles, Soraya L ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

AIF; Apoptosis; CytC; Smac Diablo and CASP 3; Sugammadex

Indexed keywords

APOPTOSIS INDUCING FACTOR; CASPASE 3; CHOLESTEROL; CYTOCHROME C; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SUGAMMADEX; GAMMA CYCLODEXTRIN DERIVATIVE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL CULTURE; CHOLESTEROL METABOLISM; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FETUS; MITOCHONDRION; NERVE CELL; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; TOXICITY TESTING; ANIMAL; CYTOLOGY; DRUG EFFECTS; NEUROMUSCULAR BLOCKING;

ANIMALS; APOPTOSIS; CELLS, CULTURED; GAMMA-CYCLODEXTRINS; NEUROMUSCULAR BLOCKADE; NEURONS; OXIDATIVE STRESS; RATS;

EID: 84881484426     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.6254     Document Type: Article

References (41)

1. Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth. Analg. 2007; 104: 575-581.
2. Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: Chemical. encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem. Int. Ed Engl. 2002; 41: 266-270.
3. Kovac AL. Sugammadex: the first selective binding reversal agent for neuromuscular block. J. Clin Anesth. 2009; 21: 444-453.
4. Abrishami A, Ho J, Wong J, et al.Sugammadex, a selective reversal.medication for preventing postoperative residual neuromuscular blockade. Cochrane Database. Syst Rev 2009;:CD007362.
5. [Internet] Food and Drug Administration. Anesthetic and Life Support Advisory Committee Meeting: briefing document (background package) for sugammadex sodium injection [online]. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4346b1-02Organon.pdf.
6. [Internet] European Medicines Agency. European Public Assessment Report for Bridion (sugammadex): scientific discussion [online].http://www.emea.europa.eu/humandocs/PDFs/EPAR/bridion/H-885-en6.pdf.
7. Laza-Knoerr AL, Gref R, Couvreur P. Cyclodextrins for drug delivery. Drug Target. 2010; 18: 645-656.
8. Akha AS, Rosa J, Jahr JS, et al. Sugammadex: cyclodextrins, development of selective binding agents, pharmacology, clinical development, and future directions. Anesthesiol Clin. 2010; 28: 691-708.
9. Farrar JT. Meeting of the Anesthetic and Life Support Drugs FDA Advisory Committee, Silver Spring, MD. Sugammadex 2008;222-225.
10. Bell RD and Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer-s disease. Acta Neuropathol. 2009; 118: 103-113.
11. Stolp HB and Dziegielewska KM: Review:Role of developmental inflammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases. Neuropathol Appl Neurobiol. 2009; 35: 132-146.
12. Waubant E. Biomarkers indicative of blood-brain barrier disruption in multiple sclerosis. Disease Markers. 2006; 22: 235-44.
13. Shlosberg D, Benifla M, Kaufer D, et al. Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat Rev Neurology. 2010; 6: 393-403.
14. Kaur C and Ling EA. Blood brain barrier in hypoxic-ischemic conditions. Curr Neurovasc Res. 2008; 5: 71-81.
15. Mook-Kanamori BB, Geldhoff M, van der Poll T, et al. Pathogenesis and pathophysiology of pneumococcal meningitis. Clin Microbiol Rev. 2011; 24: 557-591.
16. Saunders NR, Knott GW, Dziegielewska KM, Barriers in the immature brain. Cell Mol Neurobiol. 2000; 20: 29-40.
17. Valles SL, Borras C, Gambini J, et al. Oestradiol or genistein rescues neurons from amyloid beta-induced cell death by inhibiting activation of p38. Aging Cell. 2008; 7: 112-118.
18. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65: 55-63.
19. Shimizu S, Eguchi Y, Kamiiki W, et al. Induction of apoptosis as well as necrosis by hypoxia and predominant prevention of apoptosis by Bcl-2 and Bcl-XL. Cancer Res. 1996; 56: 2161-2166.
20. Peterson GL. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem. 1977; 83: 346-356.
21. Van der Bliek AM, Redelmeier TE, Damke H, et al. Mutations in human dynamin block an intermediate stage in coated vesicle formation. J Cell Biol. 1993; 122: 553-563.
22. Kelly BL and Ferreira A. Beta-Amyloid-induced dynamin 1 degradation is mediated by N-methyl-D-aspartate receptors in hippocampal neurons. J Biol Chem 2006; 281: 28079-28089.
23. Heider JG and Boyett RL. The picomole determination of free and total cholesterol in cells in culture. J Lipid Res. 1978; 19: 514-518.
24. Claudius C, Garvey LH, Viby-Mogensen J. The undesirable effects of neuromuscular blocking drugs. Anaesthesia. 2009; 64: 10-21.
25. Adam JM, Bennett DJ, Bom A, et al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J Med Chem. 2002; 45: 1806-16.
26. Yang LP and Keam SJ. Sugammadex: a review of its use in anaesthetic practice. Drugs. 2009; 69: 919-942.
27. Cammu G, De Kam PJ, Demeyer I, et al. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers. Br J Anaesth. 2008; 100: 373-379.
28. Li YC, Park MJ, Ye SK, et al. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol. 2006; 168: 1107-1118.
29. Gniadecki R. Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis. Biochem Biophys Res Commun. 2004; 320: 165-169.
30. Huang Z, Hou Q, Cheung NS, et al. Neuronal cell death caused by inhibition of intracellular cholesterol trafficking is caspase dependent and associated with activation of the mitochondrial apoptosis pathway. J Neurochem. 2006; 97: 280-291.
31. Brown DA and London E. Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol. 1998; 14: 111-136.
32. Martin M, Dotti CG, Ledesma MD. Brain cholesterol in normal and pathological aging. Biochim Biophys Acta. 2010; 1801: 934-944.
33. Simons K and Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000; 1: 31-39.
34. Schonfelder U, Radestock A, Elsner P, et al. Cyclodextrin-induced apoptosis in human keratinocytes is caspase-8 dependent and accompanied by mitochondrial cytochrome c release. Exp Dermatol. 2006; 15: 883-890.
35. Shogomori H and Futerman AH. Cholesterol depletion by methyl-β-cyclodextrine blocks cholera toxin transport from endosomes to the golgi apparatus in hippocampal neurons. J Neurochem. 2001; 78: 991-999.
36. Sponne I, Fifre A, Koziel V, et al. Membrane cholesterol interferes with neuronal apoptosis induced by soluble oligomers but not fibrils of amyloidbeta peptide. FASEB J. 2004; 18: 836-838.
37. Jeong JK, Seol JW, Moon MH, et al. Cellular cholesterol enrichment prevents prion peptide-induced neuron cell damages. Biochem Biophys Res Commun. 2010; 401: 516-520.
38. Pensalfini A, Zampagni M, Liguri G, et al. Membrane cholesterol enrichment prevents Aβ-induced oxidative stress in Alzheimer-s fibroblasts. Neurobiol Aging. 2011; 32: 210-222.
39. Clement AB, Gamerdinger M, Tamboli IY, et al. Adaptation of neuronal cells to chronic oxidative stress is associated with altered cholesterol and sphingolipid homeostasis and lysosomal function. J Neurochem. 2009; 111: 669-682.
40. Garcia-Ruiz C, Mari M, Colell A, et al. Mitochondrial cholesterol in health and disease. Histol Histopathol. 2009; 24: 117-132.
41. Koh CH, Qi RZ, Qu D, et al. U18666A-mediated apoptosis in cultured murine cortical neurons: role of caspases, calpains and kinases. Cell Signal. 2006; 18: 1572-1583.